Literature DB >> 20171519

Radiotherapy dose-volume effects on salivary gland function.

Joseph O Deasy1, Vitali Moiseenko, Lawrence Marks, K S Clifford Chao, Jiho Nam, Avraham Eisbruch.   

Abstract

Publications relating parotid dose-volume characteristics to radiotherapy-induced salivary toxicity were reviewed. Late salivary dysfunction has been correlated to the mean parotid gland dose, with recovery occurring with time. Severe xerostomia (defined as long-term salivary function of <25% of baseline) is usually avoided if at least one parotid gland is spared to a mean dose of less than approximately 20 Gy or if both glands are spared to less than approximately 25 Gy (mean dose). For complex, partial-volume RT patterns (e.g., intensity-modulated radiotherapy), each parotid mean dose should be kept as low as possible, consistent with the desired clinical target volume coverage. A lower parotid mean dose usually results in better function. Submandibular gland sparing also significantly decreases the risk of xerostomia. The currently available predictive models are imprecise, and additional study is required to identify more accurate models of xerostomia risk. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20171519      PMCID: PMC4041494          DOI: 10.1016/j.ijrobp.2009.06.090

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  29 in total

1.  Three-dimensional conformal radiotherapy for locally advanced (Stage II and worse) head-and-neck cancer: dosimetric and clinical evaluation.

Authors:  Maurizio Portaluri; Fulvio I M Fucilli; Roberta Castagna; Santa Bambace; Giorgio Pili; Francesco Tramacere; Donatella Russo; Maria Carmen Francavilla
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-06-05       Impact factor: 7.038

2.  The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy.

Authors:  Yun Li; Jeremy M G Taylor; Randall K Ten Haken; Avraham Eisbruch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-12-04       Impact factor: 7.038

3.  Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine.

Authors:  Marc W Münter; Simone Hoffner; Holger Hof; Klaus K Herfarth; Uwe Haberkorn; Volker Rudat; Peter Huber; Jürgen Debus; Christian P Karger
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-12-15       Impact factor: 7.038

4.  Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy.

Authors:  Angel I Blanco; K S Clifford Chao; Issam El Naqa; Gregg E Franklin; Konstantin Zakarian; Milos Vicic; Joseph O Deasy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-15       Impact factor: 7.038

5.  Does radiation dose to the salivary glands and oral cavity predict patient-rated xerostomia and sticky saliva in head and neck cancer patients treated with curative radiotherapy?

Authors:  Anke Petra Jellema; Patricia Doornaert; Ben J Slotman; C Rene Leemans; Johannes A Langendijk
Journal:  Radiother Oncol       Date:  2005-10-26       Impact factor: 6.280

6.  Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer.

Authors:  Amichay Meirovitz; Carol Anne Murdoch-Kinch; Mathew Schipper; Charlie Pan; Avraham Eisbruch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-07-12       Impact factor: 7.038

7.  Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer.

Authors:  Kauko Saarilahti; Mauri Kouri; Juhani Collan; Aki Kangasmäki; Timo Atula; Heikki Joensuu; Mikko Tenhunen
Journal:  Radiother Oncol       Date:  2006-03-27       Impact factor: 6.280

8.  Dose-response relationships within the parotid gland after radiotherapy for head and neck cancer.

Authors:  Barbara Bussels; Annelies Maes; Patrick Flamen; Philippe Lambin; Katrien Erven; Robert Hermans; Sandra Nuyts; Caroline Weltens; Silvia Cecere; Emmanuel Lesaffre; Walter Van den Bogaert
Journal:  Radiother Oncol       Date:  2004-12       Impact factor: 6.280

9.  Individual radiation response of parotid glands investigated by dynamic 11C-methionine PET.

Authors:  Simon Buus; Cai Grau; Ole Lajord Munk; Anders Rodell; Kenneth Jensen; Kim Mouridsen; Susanne Keiding
Journal:  Radiother Oncol       Date:  2006-03-20       Impact factor: 6.280

10.  Quality of life and salivary output in patients with head-and-neck cancer five years after radiotherapy.

Authors:  Pètra M Braam; Judith M Roesink; Cornelis P J Raaijmakers; Wim B Busschers; Chris H J Terhaard
Journal:  Radiat Oncol       Date:  2007-01-05       Impact factor: 3.481

View more
  165 in total

1.  Dosimetric and radiobiological comparison of helical tomotherapy, forward-planned intensity-modulated radiotherapy and two-phase conformal plans for radical radiotherapy treatment of head and neck squamous cell carcinomas.

Authors:  S Chatterjee; N Willis; S M Locks; J H Mott; C G Kelly
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

2.  Investigations on parotid gland recovery after IMRT in head and neck tumor patients.

Authors:  Markus Stock; Wolfgang Dörr; Carmen Stromberger; Ulrike Mock; Susanne Koizar; Richard Pötter; Dietmar Georg
Journal:  Strahlenther Onkol       Date:  2010-11-30       Impact factor: 3.621

3.  Unilateral neck therapy in the human papillomavirus ERA: accepted regional spread patterns.

Authors:  Thomas J Galloway; Miriam N Lango; Barbara Burtness; Ranee Mehra; Karen Ruth; John A Ridge
Journal:  Head Neck       Date:  2012-02-02       Impact factor: 3.147

4.  A split-parotid delineation approach for dose optimization in volumetric modulated arc therapy for nasopharyngeal carcinoma patients with parapharyngeal space invasion and level IIa cervical lymph node involvements.

Authors:  Wei Xiao; Zhixiong Lin; Wuzhe Zhang; Mei Li; Vincent W C Wu
Journal:  Br J Radiol       Date:  2016-02-03       Impact factor: 3.039

5.  Magnetic resonance sialography for investigating major salivary gland duct system after intensity-modulated radiotherapy of nasopharyngeal carcinoma.

Authors:  Dan Ou; Yunyan Zhang; Xiayun He; Yajia Gu; Chaosu Hu; Hongmei Ying; Guopei Zhu; Yongru Wu; Jian Mao; Lei Yue; Xigang Shen
Journal:  Int J Clin Oncol       Date:  2012-08-15       Impact factor: 3.402

Review 6.  Revisiting the dose constraints for head and neck OARs in the current era of IMRT.

Authors:  N Patrik Brodin; Wolfgang A Tomé
Journal:  Oral Oncol       Date:  2018-09-08       Impact factor: 5.337

7.  Modeling the dosimetry of organ-at-risk in head and neck IMRT planning: an intertechnique and interinstitutional study.

Authors:  Jun Lian; Lulin Yuan; Yaorong Ge; Bhishamjit S Chera; David P Yoo; Sha Chang; FangFang Yin; Q Jackie Wu
Journal:  Med Phys       Date:  2013-12       Impact factor: 4.071

8.  Radiotherapy effect on nano-mechanical properties and chemical composition of enamel and dentine.

Authors:  R Reed; C Xu; Y Liu; J P Gorski; Y Wang; M P Walker
Journal:  Arch Oral Biol       Date:  2015-02-27       Impact factor: 2.633

9.  Error in the parotid contour delineated using computed tomography images rather than magnetic resonance images during radiotherapy planning for nasopharyngeal carcinoma.

Authors:  Chengxin Liu; Xudong Kong; Guanzhong Gong; Tonghai Liu; Baosheng Li; Yong Yin
Journal:  Jpn J Radiol       Date:  2014-02-21       Impact factor: 2.374

10.  Assessment of Risk of Xerostomia After Whole-Brain Radiation Therapy and Association With Parotid Dose.

Authors:  Kyle Wang; Kevin A Pearlstein; Dominic H Moon; Zahra M Mahbooba; Allison M Deal; Yue Wang; Stephanie R Sutton; Britni B Motley; Gregory D Judy; Jordan A Holmes; Nathan C Sheets; Mohit S Kasibhatla; Heather D Pacholke; Colette J Shen; Timothy M Zagar; Lawrence B Marks; Bhishamjit S Chera
Journal:  JAMA Oncol       Date:  2019-02-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.